Skip to Content

Michael E. Rytting, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The Children's Cancer Hospital at The University of Texas MD Anderson Cancer Center, Leukemia/Lymphoma Section, Houston, TX

Bio Statement

Dr. Rytting graduated from the University of Michigan Medical School, completed an Internal Medicine/Pediatrics residency at the University of Texas Health Science Center-Houston, and completed a fellowship in Pediatric Hematology/Oncology at the University of Texas M.D. Anderson Cancer Center. He is currently an associate professor of pediatrics at the University of Texas M.D. Anderson Cancer Center, and he has a joint appointment in adult leukemia. Dr. Rytting specializes in pediatric leukemia and lymphoma as well as young adult acute leukemia, and his clinical research is predominantly in acute lymphoblastic leukemia in young adults. In addition he works in the pediatrics neuro-oncology section, where his focus is on ependymoma and pontine glioma.  

Education & Training

Degree-Granting Education

1990 University of Michigan, Ann Arbor, MI, MD, Medical Degree
1985 Cornell University, Ithaca, NY, BA, General Biology & Spanish Literature

Board Certifications

2001 American Board of Pediatrics - Diplomate
1998 American Board of Pediatric Hematology/Oncology - Diplomate
1995 American Board of Internal Medicine - Diplomate
1994 American Board of Pediatrics - Diplomate

Selected Publications

Peer-Reviewed Original Research Articles

1. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 4/2012. e-Pub 2/2012. PMID: 22357140.
2. Rytting ME. Lessons from ALL-REZ BFM 90: therapy for childhood leukemia based on timing and site of relapse. Curr Hematol Malig Rep 7(1):1-2, 3/2012. PMID: 22290023.
3. Georgiadou, S; Pongas Georgios; Fitzgerald N; Lewis R; Rytting M; Marom E; Kontoyiannis D. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: a 10-year, single-institution, retrospective study. Journal of the Pediatrics Infectious Disease Society, 2012.
4. Green HL, Rytting ME, Cox CS. A Rapidly Growing Lymphoma and Tumor Lysis Syndrome in a Toddler. JAAPA 23(8):32-4, 8/2010. PMID: 20821911.
5. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 10(5):833-9, 5/2010. PMID: 20345338.
6. Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M, Jaffe N. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res 373:39-50, 4/2000. PMID: 10810461.
7. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha S, Kuttesch JF, Rolston KV. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86(1):126-34, 7/1999. PMID: 10391572.
8. Ravandi F, Rytting M, Osmon C, Braud EL, Roach RW, Edwards K, Winn R, Abbruzzese JL, Pazdur R. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs 10(6):519-524, 7/1999. PMID: 10885898.
9. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol 21(3):212-18, 1999. PMID: 10363854.
10. Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Pediatr Hematol Oncol 20(5):516-517, 1998. PMID: 9787333.
11. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 10(2):365-376, 1996. PMID: 8707760.


1. DeWire M, Fouladi M, Stewart C, Wetmore C, Hakins C, Jacobs C, Yuan Y, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang E, Foreman N, Gilbert M, Gilberson R, Gajjar A. An open-label, two-stage, phse II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Neuro-Oncology 15(S1):0177, 2013.
2. Guillermo Garcia-Manero, MD1, Deborah A Thomas, MD1, Michael E. Rytting , MD2, Susan O'Brien, MD1, Anna R.K. Franklin, M.D.2, Gautam Borthakur, MD1, Monica Kwari, BSN1, Sam Dara1*, Hui Yang, MD, PhD1* and Hagop Kantarjian, MD1. Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). 52nd ASH Annual Meeting and Exposition (#867), 12/2010.
3. Michael Rytting, MD1, Hagop M. Kantarjian, MD2, Deborah A Thomas, MD2, Elias Jabbour, MD2, Anna Franklin, M.D.3*, Farhad Ravandi, MD2, Stefan Faderl, MD2, Rebecca Garris, BA2*, Tapan Kadia, MD2, Kurt Schroeder, RN2* and Susan O'Brien, MD2. Adolescent and Young Adult Patients Treated with Modified Augmented Berlin-Frankfurt-Muenster Therapy. 52nd ASH Annual Meeting and Exposition (#3250), 11/2010.

Last updated: 7/22/2015